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 SUMMARY  
 
Estrogen and selective estrogen receptor modulators (SERMs) differentially impact endometrial and 
breast cancer cell function, however, the biological basis of these differences is not established. 
Deregulated cell adhesion to the extracellular matrix, cell movement and invasion are related to 
several disorders, such as endometriosis, endometrial and breast cancer metastasis. Remodeling of 
the actin cytoskeleton is required to achieve cell adhesion and movement. Estrogen receptor (ER) 
regulates actin and cell membrane remodeling through extra-nuclear signaling cascades. The aim of 
the present study was to characterize the effects of raloxifene (RAL), tamoxifen (TAM) or of 17β-
estradiol (E2) with or without RAL or TAM on ER+T47-D breast cancer cell and on endometrial 
cell line Ishikawa or human endometrial stromal cells (ESC) cytoskeletal remodeling, migration and 
invasion. Our findings show that, when given alone, RAL induces a weak actin cytoskeleton 
remodeling in breast cancer cells, with the formation of specialized cell membrane structures 
implicated in cell motility and interaction with the extracellular matrix. However, in the presence of 
physiological amounts of estradiol, that potently drives breast cancer cell cytoskeletal remodeling 
and motility, RAL displays a powerful inhibitory effect on estrogen-promoted cell migration and 
invasion. These actions are plaid through an interference of RAL with an extra-nuclear signaling 
cascade involving G proteins and the RhoA-associated kinase, ROCK-2, linked to the recruitment 
of the cytoskeletal controller, moesin. Hence, in the presence of E2, RAL acts as an ER antagonist 
on a set of cellular events implicated with the process of breast cancer migration and metastasis. 
Furthermore, we show that administration E2 and TAM to Ishikawa or to ESC also results in 
remodeling of actin fibers and cell membrane. This is linked to rapid phosphorylation on moesin 
and enhanced migration and invasion of normal and Ishikawa cells. On the contrary RAL alone 
does not result in moesin activation or actin remodeling in endometrial cells. When endometrial 
cells are exposed to E2 in the presence of TAM or RAL, both SERMs interfere with the recruitment 
of moesin, with the remodeling of the cytoskeleton, and with cell movement and migration induced 
by E2. The differential actions of E2, TAM and RAL are linked to a distinct modulation of the 
extra- nuclear signaling of ER to G proteins and to the Rho-associated kinase. These findings 
increase our understanding of the actions of estrogen and SERMs in breast cancer and endometrial 
cells and highlight potential molecular targets to interfere with the estrogen-related altered cell 
adhesion encountered in endometrial disorders or breast cancer progression and/or metastasis 
induced by estrogens in postmenopausal women. 
 
 
 
 RIASSUNTO 
Gli estrogeni e i modulatori selettivi del recettore degli estrogeni (SERMs) hanno una azione 
diversa sulle funzioni delle cellule endometriali e delle cellule di tumore mammario, anche se le 
basi biologiche di queste differenze non sono ancora ben note. La deregolazione dell’ adesione 
cellulare alla matrice extracellulare, del movimento cellulare e dell’invasione, si ritrovano in diverse 
patologie come l’endometriosi e i tumori endometriali e mammari metastatici. Per permettere 
l’adesione cellulare e il movimento è richiesto il rimodellamento del citoscheletro actinico. Il 
recettore degli estrogeni (ER) regola il rimodellamento dell’actina e della membrana cellulare 
attraverso una via di segnale extranucleare. Lo scopo di questo lavoro è caratterizzare gli effetti del 
raloxifene (RAL), tamoxifene (TAM) e del 17β-estradiolo (E2) con o senza RAL o TAM su cellule 
di tumore mammario ER+T47-D e su cellule endometriali della linea Ishikawa o cellule 
endometriali stromali umane (ESC), per quanto concerne il rimodellamento citoscheletrico, la 
migrazione e l’invasione. I nostri risultati dimostrano che, quando somministrato da solo il RAL 
induce un debole rimodellamento del citoscheletro actinico in cellule di tumore mammario, con la 
formazione di strutture specializzate della membrana cellulare implicate nella motilità cellulare e 
nell’interazione con la matrice extracellulare. Comunque in presenza di fisiologiche quantità di 
estradiolo, il quale potenzialmente guida il rimodellamento citoscheletrico e la motilità in cellule di 
tumore mammario, il RAL esercita un potente effetto inibitorio sulla migrazione cellulare e 
l’invasione promossa dagli estrogeni. Queste azioni sono legate ad una interferenza del RAL con 
una via di segnale extranucleare che coinvolge una proteina G e la RhoA-associated kinase, ROCK-
2, implicata nel reclutamento della proteina regolatrice del citoscheletro, moesin. Dunque, in 
presenza di E2, il RAL si comporta come un antagonista dell’ER in una serie di eventi cellulari 
implicati nei processi di migrazione e metastasi nel cancro della mammella. Inoltre, abbiamo visto 
che la somministrazione di E2 e TAM a cellule Ishikawa o ESC porta anche ad un rimodellamento 
delle fibre actiniche e della membrana cellulare. Questo è legato ad una rapida fosforilazione di 
moesin e ad un’incremento della migrazione e dell’invasione delle cellule Ishikawa normali. Al 
contrario il RAL da solo non determina un’attivazione di moesin o un rimodellamento actinico in 
cellule endometriali. Quando le cellule endometriali sono esposte all’E2 in presenza di RAL o 
TAM, entrambi i SERMs interferiscono tramite il reclutamento di moesin, con il rimodellamento 
citoscheletrico e con il movimento cellulare e la migrazione indotti da E2. Le differenti azioni 
dell’E2, TAM e RAL sono legate a distinte modulazioni del segnale extranucleare dell’ER verso le 
proteine G e ROCK-2. Queste scoperte migliorano le nostre conoscenze a proposito delle azioni 
degli estrogeni e dei SERMs nel tumore mammario e nelle cellule endometriali e mettono in 
evidenza potenziali target molecolari per andare a interferire con le alterazioni dell’adesione 
 cellulare estrogeno-correlate che si ritrovano nelle malattie endometriali e nella progressione e 
metastasi del tumore mammario, riscontrati nelle donne in post-menopausa. 
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1-INTRODUCTION 
1.1-Overview on estrogens 
Estrogens, like other steroid hormones, are naturally occurring cyclopentanophenanthrene 
compounds whose synthesis begins with cholesterol. Estrogens play key roles in development and 
maintenance of normal sexual and reproductive function in men and women [1] although; their 
levels are significantly higher in women of reproductive age. They are mainly produced by the 
ovary and in part by the adrenal cortex, and three estrogens occur naturally in the female [2-3]. In 
premenopausal women, 17β-estradiol (E2), produced by the ovary granulosa, is the estrogen 
produced in the largest quantity and is the most potent as it has the highest affinity for its receptors. 
In pre-menopausal women, circulating estradiol levels fluctuate from 40 to 200-400 pg/mL during 
the menstrual cycle [2]. After menopause, estradiol levels drop to less than 20 pg/mL. The second 
estrogen is estrone (E1), a less potent metabolite of estradiol. Estrone is produced from 
androstenedione, the immediate precursor of estrone, in the liver and adipose tissue. In post-
menopausal women, the ovary ceases to produce estradiol while the adrenal gland continues to 
produce androstenedione. As the result, the level of estrone remains unchanged while the plasma 
level of estradiol falls significantly. The third endogenous estrogen is estriol (E3), also a metabolite 
of estradiol. Estriol is the principal estrogen produced by the placenta during pregnancy, and is 
found in smaller quantities than estradiol and estrone in non-pregnant women [2-3]. In the target 
tissues such as reproductive organs, estrogens exhibit important biological functions. Among these, 
the ovarian cycle, the development of both sexual primary and secondary characters is dependent on 
estrogen [4]. Besides regulation of physiological functions in reproductive tissues, estrogens exert a 
vast range of biological effects and influence many other physiological processes in mammals 
including cardiovascular health, bone integrity, cognition, and behavior [1]. 
Estrogens play important roles in bone homeostasis, being involved in modeling of bone during 
adolescence. They initiate pubertal growth and later limit longitudinal bone growth by inducing 
closure of the epiphysial growth plate. Even in adult life, sex steroids appear to influence the 
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remodeling of bone. E2, in particular, is crucial for the maintenance of bone mass in females [5] as 
is evident from the rapid loss of trabecular bone and development of osteoporosis that occurs after 
ovariectomy or at menopause [6]. 
Estrogen appears to be protective in the cardiovascular system, in part due to favourable modulation 
of serum lipid profiles [7]. The 30% of these effects are due to a reduction of total cholesterol by 
increasing the LDL receptor (LDLr) expression in the liver [8] and inhibiting the LDLr oxidation at 
vascular level [9]. Recent evidence indicates that the 70% of estrogen effect is also due to its direct 
action on the vasculature, as demonstrated by gender differences in smooth muscle contractility, 
with a greater response to noradrenaline or phenylephrine in aortas isolated from male than female 
rats [10]. E2 rapidly induces the activity of endothelial nitric oxide synthase (eNOS), which 
produces the vasodilator nitric oxide (NO) [11]. Furthermore, estrogens are able to prevent the 
proliferation and the migration of vascular smooth muscular cells (VSMC) both directly [12] and 
indirectly blocking the mitogenic action of growth factors [13]. Prior to menopause, women have a 
lower incidence of coronary heart disease compared with age-matched men [14]. Moreover, 
estrogen replacement therapy reduces mortality due to coronary heart disease in post-menopausal 
women [15]. Deprivation of estrogens by ovariectomy results in enhanced vascular contraction in 
aortas of female rats [10]. 
Studies in humans also demonstrate a beneficial vascular action of estrogen, with endothelium-
dependent vasodilatation being enhanced by the administration of 17β-estradiol at physiological 
levels [16]. 
In central nervous system, estrogen has been found to contribute to promote synapse formation and 
plasticity and to limit neuronal damage and death, besides its capability to protect from 
neurodegenerative process. Furthermore, the 17β-estradiol plays an important role as antioxidant 
reducing the oxygen reactive species (ROS) by increasing the protein level of tioredoxin, an 
important protein that protect from lipid peroxidation after oxidative stress [17].  
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Postmenopausal women are in an estrogen-deprived state and are at risk for stroke and other 
neurodegenerative diseases [18]. Epidemiological evidence suggests that postmenopausal estrogen 
therapy (ET) reduces the risk or delays the onset of Alzheimer disease [19]. Estrogen loss from 
natural or surgical menopause has been associated with a decline in cognitive function [20] that is 
reversed by ET. ET has been shown to affect cognitive function during brain aging as well [21]. 
Given this widespread role for estrogen in human physiology, it is not surprising that estrogen is 
also implicated in the development or progression of numerous diseases, which include but are not 
limited to osteoporosis, neurodegenerative diseases, cardiovascular disease, insulin resistance, lupus 
erythematosus, endometriosis, obesity and various types of cancer (breast, ovarian, colorectal, 
prostate, and endometrial). Indeed, in addition to proliferative effects on normal cells, estrogen is 
considered as a stimulant for the initiation and promotion of tumors in these organs [4]. This 
expanded view of estrogen action reflects the findings of a large number of clinical and 
epidemiological studies which gathered on the effects of exogenous estrogen administration on the 
post-menopausal women health.  
 
1.2-Estrogen receptors 
The biological actions of estrogens are traditionally mediated by binding to one of two specific 
estrogen receptors (ER), ERα or ERβ, that are encoded by different genes located on different 
chromosomes (locus 6q25.1 and locus 14q23-24.1, respectively) [22]. ERα and ERβ, like all the 
members of the nuclear receptor super-family, are modular proteins sharing common regions, 
named A/B, C, D, and E/F, as well as a high sequence homology (Fig. A). These regions participate 
in the formation of independent but interacting functional domains. The N-terminal domain (A/B 
region) is involved in both inter-molecular and intra-molecular interactions as well as in the 
activation of gene transcription. The DNA binding domain (DBD, C region) allows ER to dimerize 
and to bind to the specific ERE sequence on DNA through its two “zinc finger” structures. The 
hinge domain (D region) has a role in receptor dimerization and in binding to chaperone heat-shock 
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proteins (Hsp). The ligand binding domain (LBD, E/F region, C-terminal) comprises the E2-binding 
domain and works, synergistically with the N-terminal domain in the regulation of gene 
transcription [23]. 
 
 
 
Fig. A. A schematic structural comparison of human ERα and ERβ functional domains. Receptor domains are 
illustrated with different colored boxes, and the approximate size of each domain is indicated. The A/B domain contains 
the ligand-independent transcriptional-activation function AF-1, the C domain represents the DNA-binding-domain 
(DBD), the D domain corresponds to the hinge region, and the E domain contains the hormone-binding domain (LBD) 
and the hormone-dependent transcriptional-activation function AF-2. The number inside each box of ERβ refers to the 
percentage of amino acid identity. 
 
Numerous mRNA splice variants exist for both receptors in both diseased and normal tissue, 
although the corresponding protein products have been difficult to confirm [24]. Because these 
splice variants are frequently coexpressed with their wild-type counterparts, the exact function and 
potential role of these variants in normal physiology and human disease remain to be elucidated.  
 
1.21-ER tissue distribution 
Both ERs are widely distributed throughout the body, displaying distinct or overlapping expression 
patterns in a variety of tissues [25, 26]. ERα and β are, however, coexpressed in a number of tissues 
including the mammary gland, epididymis, thyroid, adrenal, bone, and certain regions of the brain. 
Although both ER subtypes may be expressed in the same tissue, they might not be expressed in the 
same cell type. In the rat ovary, ERβ is the predominant ER in the granulosa cells, whereas ERα is 
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largely present in the thecal and interstitial cells [27]. The uterus and pituitary gland are special in 
that ERβ is expressed during development and ERα when the tissue matures [28].  
 
1.22-Estrogen receptor mechanism of action  
Estrogens induce cellular changes through several different mechanisms (Fig. B). In the “classical” 
mechanism of action, estrogens diffuse into the cell membrane and bind to ERs causing ERs to 
dissociate from heat shock proteins, to dimerize and to translocate into the nucleus.  
 
 
Fig. B. Models of estrogen action. In the “classical” pathway of estrogen action (i), estrogen or other selective estrogen 
receptor modulators (SERMs) bind to the estrogen receptor (ER), a ligand-activated transcription factor that regulates 
transcription of target genes in the nucleus by binding to estrogen response element (ERE) regulatory sequences in 
target genes and recruiting coregulatory proteins (CoRegs) such as coactivators. Rapid or “nongenomic” effects of 
estrogen may also occur through the ER located in or adjacent to the plasma membrane (ii), which may require the 
presence of “adaptor” proteins, which target the ER to the membrane. Activation of the membrane ER leads to a rapid 
change in cellular signaling molecules and stimulation of kinase activity, which in turn may affect transcription. Lastly, 
other non-ER membrane-associated estrogen-binding proteins (EBPs) may also trigger an intracellular response (iii). 
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The nuclear ERα- or ERβ-E2 complex directly binds DNA through the ERE (estrogen responsive 
element) sequences or indirectly through protein-protein interactions with activator protein-1 (AP-1) 
or stimulating protein (Sp-1), resulting in recruitment of coregulatory proteins (coactivators or 
corepressors) to the promoter, increased or decreased mRNA levels, protein synthesis, and 
physiological responses [3].  
This classical, or “genomic,” mechanism typically occurs over the course of hours. In contrast, 
estrogen can act more quickly (within seconds or minutes) via “nongenomic” mechanisms [29], 
either through the ER located in or adjacent to the plasma membrane, or through other non-ER 
plasma membrane–associated estrogen-binding proteins (Fig. B), resulting in cellular responses 
such as increased levels of Ca2+ or NO, and activation of kinases.  
Various signaling pathways are activated upon E2 binding to ERs. These rapid events may be 
classified into four main signaling cascade: phospholipase C (PLC)/protein kinase C (PKCs) [8], 
Ras/Raf/MAPK [30], phosphatidyl inositol 3 kinase (PI3K)/AKT [31 , 32], and cAMP/protein 
kinase A (PKA) [33]. These pathways present numerous interactions with several other pathways. 
The ERα:E2 complex interacts with the IGF-1 receptor, leading to IGF-1 receptor activation and 
hence to MAPK signaling pathway activation [34]. In addition, the ERα:E2 complex activates the 
EGF receptor by a mechanism that involves activation of guanine nucleotide exchange proteins (G-
proteins), Src, and matrix metalloproteinases, leading to an increase in extracellular regulated 
kinases (ERK) and PI3K/AKT activities [35]. In endothelial cells the Src/PI3K/AKT pathway 
mediates rapid E2-dependent activation of eNOS and the release of nitric oxide. AKT and PKC 
could also modulate the MAPK pathway through Raf phosphorylation [11, 32]. It is important to 
note that activation of signaling pathways by E2 is cell type-specific. Indeed, the effect of E2 on 
PKC activity has been observed in the preoptic area of female rat brain slices, but not in the 
hypothalamus or cortex [36]. The activation of G-protein/Src/PI3K/MAPK pathway by E2 was 
evident in late, but not early, differentiated rat pre-adipocytes [37]. The differential requirement of 
Src/PI3K or intracellular calcium for MAPK activation is also observed in diverse cell types [37-
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38]. As a whole, these studies indicate that the rapid actions of E2 depend on a number of 
conditions such as the set of signal transduction molecules and downstream targets present in the 
target cell, thus the responses are likely to be diverse. All these results point to the concept that ERα 
is the primary endogenous mediator of rapid E2 actions. 
 
1.3-Selective Estrogen Receptor Modulators (SERM) 
The central role of the ER signaling network in cancer, cardiovascular disease, osteoporosis, and 
neurological disease and an increasingly detailed understanding to the underlying cell biology have 
made ER an attractive target for pharmacological intervention. Selective estrogen receptor 
modulators (SERMs) are ER ligands that can have varying agonist or antagonist activities given the 
cell context [39-40]. They have been developed and characterized to obtain more favorable tissue 
and receptor subtype selective effects [1, 41]. These ligands that display tissue-selective 
pharmacology: as anti-estrogens (or antagonists) they oppose the action of estrogens in certain 
tissues, while mimicking the action of endogenous estrogens (agonists) in others.  
For instance, Tamoxifen (TAM) is the prototypical SERM that, because of its agonist activity in the 
liver, reduces serum total cholesterol and LDL levels [42]; is an ER agonist in bone and uterus, but 
is an antagonist in the breast and has been a safe and effective adjuvant endocrine therapy for breast 
cancer for almost 20 years. Unfortunately TAM, like 17β-estradiol (E2), increases endometrial cell 
proliferation [43], and its use in breast cancer patients is associated with an increased risk of 
endometrial hyperplasia and cancer [44-45].  
Raloxifene (RAL), another SERM, is similar to TAM in its tissue-specific agonist/antagonist profile 
exhibits greater agonist activity in bone and less in the uterus [46] hence its use for the prevention 
and treatment of postmenopausal osteoporosis. RAL has no stimulatory effect in the endometrium 
[47] and recent studies even suggest that the use of this SERM might result in reduced incidence of 
endometrial cancer [48]. Therefore, this compound represents a potentially good tool to maintain 
and improve bone quality in postmenopausal women, while reducing breast cancer risk. Recently, 
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RAL has received from the FDA the indication for its use as primary chemoprevention of breast 
cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. 
Whether a SERM is an ER agonist or antagonist in a particular tissue depends on several factors. 
Binding of a SERM to the ER causes a specific conformational change in the receptor, and the 
resulting 3D structure determines which coactivators and/or corepressors are recruited to the 
promoter (Fig. C).  
 
 
 
 
Fig. C. Differential ER structure and coactivator recruitment by ER agonists, antagonists, and SERMs. Upon 
binding ER ligands such as estradiol or SERMs, the receptor undergoes a conformational change, allowing the ER to 
exist in a spectrum of conformations from active to inactive depending on the nature of the bound ligand. This 
conformation, in turn, regulates the recruitment of specific transcriptional coregulatory proteins and the resulting 
transcriptional apparatus. Coactivators such as SRC1 bind to the active (agonist-bound) form of the receptor and 
activate transcription, while corepressors interact with the antagonist-bound receptor, inhibiting transcription. 
Depending on the cellular and promoter context, both unique and overlapping sets of genes may be regulated by various 
ligands.  
 
Thus, the relative level of corepressors and coactivators in a particular tissue is a critical 
determinant of a SERM’s agonist/antagonist activity. For example, TAM recruits a coactivator 
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complex to estrogen-regulated genes in endometrial cells but a corepressor complex to the same 
gene in breast cancer cells [49]. The specific coregulators recruited to a particular promoter also 
depend on the type of ER-dependent regulatory sequences that are present in the promoter, such as 
estrogen response elements or other transcription factor binding sites, such as AP1. Lastly, the 
ERα/ERβ ratio varies between tissues, and which ER form predominates also affects SERM activity. 
Thus, the physiological response to a particular SERM results from a combination of factors, 
including its chemical structure and the cellular and promoter context in which the SERM acts. 
In parallel with the development of therapeutic strategies based on the modulation of ER activity, 
compounds that inhibit the production of estrogen have also been generated and are currently in use 
clinically. Inhibitors of aromatase, the enzyme that converts androgens to estrogens, have been 
successfully used in the treatment of breast cancer and other diseases. Thus, targeting both the ER 
and the production of its activating ligand provides complementary strategies for the management 
of estrogen-regulated diseases. 
 
1.4-ERs and cancer 
1.41-Breast cancer: Estrogen is implicated in the development of breast cancer, based on data from 
both clinical and animal studies; risk factors associated with breast cancer reflect cumulative 
exposure of the breast epithelium to estrogen [50]. Two current hypotheses exist to explain this 
relationship [51]. In the first, binding of estrogens to the ER stimulates proliferation of mammary 
cells, increasing the target cell number within the tissue, and the increase in cell division and DNA 
synthesis elevates the risk for replication errors, which may result in the acquisition of detrimental 
mutations that disrupt normal cellular processes such as apoptosis, cellular proliferation, or DNA 
repair. In the second hypothesis, estrogen metabolism leads to the production of genotoxic by-
products that could directly damage DNA, again resulting in point mutations. There is evidence that 
estrogen may act through both mechanisms to initiate and/or promote mammary cancer. 
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Currently, both SERMs and aromatase inhibitors are used in the treatment of breast cancer, and 
patients whose tumors are ER-positive respond well to these endocrine therapies. Further, both 
TAM and RAL have proven effective as chemopreventative agents for breast cancer in high-risk 
women [46]. The randomized, clinical Raloxifene Use for the Heart (RUTH) trial is currently 
testing the efficacy of chronic raloxifene treatment in postmenopausal women in (a) reducing the 
incidence of coronary heart disease (multiple endpoints), and (b) reducing the risk of invasive breast 
cancer in women at high risk for major coronary events [52]. In addition, ICI 182,780, an ER 
antagonist that inhibits ER activity and reduces ER levels, is also used in the treatment of breast 
cancer. ERα expression is associated with more differentiated tumors and a more favorable 
prognosis, and although the potential role of ERβ in tumor progression is controversial, studies of 
ERβ protein levels suggest that it is also a favorable prognostic indicator [24]. 
Both cell culture and animal model studies indicate that the ER is involved in mammary gland 
development and mammary cancer. Studies in ERα knockout (αERKO) mice demonstrate that ERα 
is required for normal mammary gland development [53]. Adult αERKO females exhibit mammary 
glands that are similar to those of normal prepubertal female mice, i.e., lacking ductal development 
and terminal end buds. In Neu/ErbB2 knock-in transgenic mice, which develop mammary tumors 
with a long latency period, loss of ERα resulted in no incidence of tumor development, indicating 
that ERα contributes to the development and/or progression of Neu-induced carcinogenesis in this 
model. However, in a second Neu model, αERKO animals were crossed with mice expressing a 
mammary-specific mutant Neu, which was constitutively active (resulting in much higher levels of 
the oncogene compared with the first model). In this second model, females that lacked ERα still 
developed mammary tumors, although tumor onset was delayed [54]. These studies indicate that 
ERα influences tumor progression but not incidence for Neu-induced carcinogenesis when the 
oncogene is highly expressed. In the C3(1)/T(AG) mouse model of estrogen-promoted mammary 
tumorigenesis, mammary tumor incidence is minimized with the loss of ERα expression [55]. These 
data suggest that ERs may serve different functions, depending on the stage of tumor development 
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and/or progression. Thus, both basic science and clinical data indicate that ERα is a primary 
mediator of estrogenic actions in breast cancer. 
 
1.42-Endometrial cancer: Endometrial cancer is one of the most common female genital tract 
malignancies with increasing morbidity reported worldwide in recent years.  Approximately 70–
80% of sporadic endometrial carcinomas are distinguished as type I carcinomas and are associated 
with endometrial hyperplasia, hyperestrogenism, and expression of ER. The remaining 20% 
constitute type II carcinomas, are generally unrelated to estrogen, and exhibit negative or low ER 
expression [56].  
It is well-known that risk for endometrial adenocarcinoma increases in patients with high estrogen 
levels that are unopposed by progestins, since estrogen exhibits growth-promoting properties in 
endometrial cancer cells [57-58]. Estrogen predominance induces the typical sequence of 
endometrial hyperplasia, finally resulting in the development of endometrial cancer [59] and 
estrogen is the most important known factor that stimulates the growth of endometriosis disease. 
The prognosis for endometrial cancer is excellent in the early stages, when the tumor is confined to 
the endometrium or to the inner of the myometrium but unfortunately in pathological conditions 
such as cancer, cell migration is a critical process, because it is required for cancer cell spread, 
invasion, and metastasis [60-62].  
 
1.5-Estrogen and cell movement 
Recent evidence points out those sex steroids also regulate cell mobility via the regulation of 
rearrangement of cell actin cytoskeleton, which may be extremely important for the function of cell 
movement [63]. We have recently described the presence of rapid actions of estrogens on the 
assembly of actin fibers in human endothelial cells and breast cancer cells [64-65]. In particular, the 
exposure of these cells to physiological concentrations of estradiol leads to a rapid rearrangement of 
actin with a loss of stress fibers and the formation of cortical actin complexes. 
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This actin remodeling parallels the formation of focal adhesion complexes and the development of 
endothelial and breast cancer cells membrane specialized structures, such as ruffles and 
pseudopodia, which are implicated in cell adhesion to the extracellular matrix, cell-cell interaction 
and cell movement. These phenomena depend on the rapid activation by phosphorylation of the 
actin-regulatory protein moesin [65]. 
 
1.51-Ezrin/radixin/moesin (ERM) family 
Moesin, a member of the ezrin/radixin/moesin (ERM) family, is an actin-binding protein that plays 
an important role in cell motility by linking the actin cytoskeleton to a variety of membrane-
anchoring proteins [66-67]. Interestingly, ERM proteins have been recently reported as key 
regulators of metastasis in aggressive cancers [68-69]. 
Estrogen activates moesin in endothelial and breast cancer cells through a rapid, extra-nuclear 
signaling cascade originated by the interaction of ERα with the G protein Gα
13
. This process leads 
to the recruitment of RhoA and of the Rho associated kinase, ROCK-2 and to moesin activation. 
This pathway leads to the formation of membrane ruffles and pseudopodia which interact with the 
extracellular matrix and with nearby cells, thus promoting cell migration [64-65].  
Although this is a relatively recent area of investigation, it significantly expands our perception of 
the scope of sex steroid nongenomic signaling and sheds new insight into their ability on the control 
of cell movement, which maybe critically relevant for several of physiological or path-physiological 
processes, such as endometriosis, dysfunctional uterine bleeding, endometrial hyperplasia or cancer 
metastasis.  
 An unbalanced exposure to estrogen and progesterone is a key factor for the development of 
endometrial carcinoma [58], and the modification by sex steroids of cell morphology and motility 
through the actin cytoskeleton might represent a step in endometrial transformation and may play a 
role for endometrial cancer cell spread, invasion and metastasis. 
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2-AIM 
The distinct control of estrogen receptors by natural estrogens or by the available SERMs is the 
basis for their different effects in some tissues, such as the endometrium and breast.  
At present, there is no available information on whether these differential tissue specific effects may 
be related to discrepant actions of estrogen and SERMs on endometrial or breast cell cytoskeleton. 
The clinical efficacy of adjuvant therapy with TAM on estrogen receptor positive (ER+) breast 
cancers is well established [70]. However, little is known on the possible effects of RAL on breast 
or endometrial cancer progression and metastasis.  
The aim of the present study was to establish whether 17β-estradiol (E2), TAM or RAL might exert 
distinct regulatory actions on the actin cytoskeleton of human breast cancer T47-D cells of human 
endometrial stromal cells, or of a human immortalized endometrial cell line Ishikawa leading to 
differences in cell motility. To this extent, we investigated if estradiol or the two SERMs 
differentially recruit the rapid signaling cascades that target the actin-binding protein moesin. 
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3-RESULS 
3.1-Results in Breast Cancer T47-D cells 
3.11-RAL induces a rapid rearrangement of the actin cytoskeleton in ER+ T47-D breast 
cancer cells. 
We previously demonstrated that 17-estradiol (E2) rapidly induces a rearrangement of the actin 
cytoskeleton in a nongenomic and time-dependent manner in human endothelial cells [65] as well 
as in ER+ T47-D breast cancer cells [64]. In the present study, steroid- and serum-deprived T47-D 
breast cancer cells were treated with RAL (10 nM) for different time points and the actin 
cytoskeleton was visualized with immunofluorescence after staining with phalloidin linked to Texas 
Red. Actin fibres in unstimulated controls were arranged longitudinally through the major axis of 
the cells which displayed regular cell membrane borders (Fig. 1A). Treatment with RAL from 2 to 
20 minutes led to a rapid change of the organization of the actin fibres. Actin translocated from the 
cytoplasm toward the edge of the cell membrane, forming a typical cortical actin complex, in 
association with the formation of specialized membrane structures, such as pseudopodia (Fig. 1A). 
These morphological changes were time-dependent and transient, being maximal after 15-20 
minutes and then showing a progressive reversal to the basal arrangement between 30 and 60 
minutes (Fig. 1A). In addition, treatment with RAL at different concentrations (from 0.1 to 100 nM) 
resulted in a remodeling of actin fibres that was present at all concentrations tested (Fig. 1B). 
Consistently with our previous data [64], E2 (10 nM) also induced a rapid actin remodeling in T47-
D cells (Fig. 1B). 
 
3.12-RAL rapidly activates the actin-regulatory protein, moesin in breast cancer cells. 
Based on our previous finding that the actin-regulatory protein moesin mediates the cytoskeletal 
effects of estrogen [64-65] we studied whether RAL stimulated actin rearrangement through this 
protein. Indeed, the cellular level of Thr
558
-phosphorylated moesin, which is functionally activated 
[71], rapidly increased in T47-D cells treated with RAL (10 nM) from 2 to 15 minutes and then 
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declined to the basal level after 20-60 minutes (Fig. 2A), time-consistently with the kinetics of 
RAL-induced actin rearrangement. Exposure of T47-D cells to different concentrations of RAL 
(from 0.1 to 100 nM) for 15 minutes resulted in an activation of moesin that was similar for all the 
RAL doses, and comparable to that of E2 (10 nM) (Fig. 2B). The total cell content of ir-moesin did 
not change during this period (Fig. 2A-B). 
 
3.13-RAL effects on breast cancer cell migration 
To relate the RAL-induced actin cytoskeleton remodeling and moesin activation with increased cell 
motility, we performed horizontal migration assays with T47-D cells. In order to distinguish cell 
migration from cell proliferation, Cytosine β-D-arabinofuranoside hydrochloride (10 µM), a 
selective inhibitor of DNA strand separation that does not block RNA synthesis, was used to arrest 
cell proliferation. Treatments with different concentrations of RAL (from 0.1 to 100 nM) 
significantly increased the number of cells that migrated through the starting line, as well as the 
mean length of migration compared to control (Fig. 3A). E2 as well resulted in a significant 
increase of horizontal migration of T47-D cells (Fig. 3A). Interestingly, E2 and RAL-treated T47-D 
cells displayed different patterns of migration. In the presence of E2, these migrating cells formed a 
“compact” migration front while in the presence of RAL they displayed a variable tendency to 
move. Some migrating cells moved forward more rapidly than others thus creating a discontinuous 
migration front. Overall, T47-D cells treated with RAL displayed longer median migration 
distances, but the number of migrating cells was numerically lower than in the presence of E2 (Fig. 
3B). 
 
3.14-RAL counteracts the E2-induced remodeling of the actin cytoskeleton in T47-D cells. 
As a SERM, RAL can compete with estrogens by binding to estrogen receptors and differently alter 
estrogen action depending on the tissue. T47-D cells exposed to E2 (10 nM) together with 
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increasing concentrations of RAL revealed that the E2-induced actin rearrangement and formation 
of cell membrane structures are attenuated in the presence of RAL, in a dose-related fashion (Fig. 
4A). 
 
3.15-RAL interferes with E2-induced moesin phosphorylation and cell migration in T47-D 
breast cancer cells. 
The co-administration of RAL with E2 (10 nM) resulted in a concentration-related repression of the 
moesin activation induced by estradiol. The effect of E2 was completely blunted in the presence of 
an equimolar amount of RAL (Fig 4B). The effect of the co-administration of E2 and RAL changes 
depending on the amount of E2. Indeed, in the presence of lower E2 concentration (1 nM or 0.1nM, 
corresponding to follicular peak or to postmenopausal E2 levels, respectively) a potentiation of 
moesin phosphorylation can be seen with the addition of low RAL concentrations, while a 
progressive inhibition of moesin is obtained in the presence of higher RAL amounts (Fig. 4C-D). 
As expected, E2 significantly increased the migration of T47-D breast cancer cells (Fig. 5A-B). 
When the two drugs were co-administrated, RAL blocked E2-induced cell migration in a 
concentration-related manner. RAL affected both the absolute number of migrating cells as well as 
the median migration distance (Fig. 5A-B). 
 
3.16-RAL induces rearrangements of the actin cytoskeleton, moesin activation and cell 
migration through an ER and G protein-dependent signaling pathway  
To determine the signaling cascades involved in the action of RAL we examined the effect of 
different inhibitors of intracellular pathways that have been associated with rapid estrogen signaling 
in human cells [29; 64-65; 71] . The RAL-induced actin rearrangement as well as moesin activation 
was significantly reduced by the ER antagonist ICI 182,780, by the G protein inhibitor pertussis 
toxin (PTX) and by the inhibitor of the kinase that is responsible for moesin phosphorylation, 
RhoA-associated kinase (ROCK-2), Y-27632. On the opposite, PD98059, an inhibitor of the ERK 
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1/2 mitogen activated protein kinase (MAPK) cascade did not influence the effect of RAL (Fig. 6A-
B). These findings suggest that both ER and G proteins are required for moesin phosphorylation. 
 In agreement, the horizontal migration of T47-D breast cancer cells induced by RAL was abrogated 
by the addition of ICI 182,780, of PTX and Y-27632, indicating that an ER/G protein/ROCK 
cascade is implicated in the signaling of RAL to T47-D cell migration. No significant reduction of 
cell migration was found in the presence of PD98059 (Fig. 7A-B). 
 
3.17-RAL effects on T47-D cell invasion 
Finally, we investigated the effects of RAL and E2 on breast cancer cell invasion of a three-
dimensional matrix and compared the actions of these compounds with those of tamoxifen (TAM), 
a SERM commonly used to counteract the progression of ER+ breast cancer in clinical practice. E2, 
RAL or TAM all promoted cell invasion when used alone (Fig 8A). E2 was the most potent among 
these compounds. The effects of RAL on cell invasion were blocked by interfering with ERs, G 
proteins and ROCK. Both TAM as well as RAL reduced the E2-induced invasion of breast cancer 
cells, and the effects of RAL were concentration-related (Fig. 8A-B). 
 
3.2-Results in endometrial cells 
3.21-Effects of estradiol, tamoxifen and raloxifene on endometrial Ishikawa cell membrane 
and actin cytoskeleton remodeling 
In order to test the hypothesis that estrogen and SERMs might have different effects also on 
endometrial cancer cell morphology we assayed the effects of estradiol, tamoxifen or raloxifene on 
actin fibres arrangement in ER+ Ishikawa endometrial adenocarcinoma cells. E2, TAM and RAL 
were provided to cells at different concentrations (0.1-100 nM) for 15 minutes. At baseline, actin 
fibres were arranged longitudinally in Ishikawa cells, which displayed regular cell borders (Fig. 9A-
C). In cells exposed to E2 or TAM, a rapid loss of stress fibres, indicated by the disappearance of 
the regular, longitudinally-oriented cytoplasmic actin fibres [72], and a shift of the fibres toward the 
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edge of the membrane were seen (Fig. 9A-B). This cytoskeletal remodeling was accompanied by 
the development of membrane ruffles, visible identified such as sheet-like membrane protrusions, 
and of pseudopodia (identified as weakly adherent longitudinal protrusions) [72] at sites enriched in 
actin (Fig. 9A-B). In contrast, cells treated with RAL showed no modification of actin organization 
at any concentration tested (Fig. 9C). These changes corresponded to parallel modifications in the 
thickness of the cell membrane and in the actin fluorescence intensity ratio between membrane and 
cytoplasm (Fig. 9A-C). 
The pattern of remodeling of actin fibres and cell membrane observed in Ishikawa cells with 
estrogen, TAM or RAL was also found in primary human endometrial stromal cells (ESC) (Fig. 
9D). 
 
3.22-Estradiol and tamoxifen, but not raloxifene, recruit the actin-binding protein moesin in 
Ishikawa cells 
Based on our previous finding that the actin-regulatory protein moesin mediates the cytoskeletal 
effects of estrogen in endothelial and breast cancer cells [64-65], we studied whether this protein 
might play a role in the endometrial actin rearrangement induced by E2 and TAM. The 
phosphorylation on Thr
558
 of moesin was enhanced by short (15 min) incubations with E2 and with 
TAM (starting from 1 nM), but not by RAL in Ishikawa cells (Fig. 10A-C). Similar effects were 
found in ESC (Fig. 10D). The total cell content of moesin did not change during this period (Fig. 
10A-D). 
 
3.23-Estradiol and tamoxifen, but not raloxifene, trigger moesin activation and cytoskeletal 
remodeling in Ishikawa cells via an ER/G protein/ROCK-dependent signaling pathway 
The recruitment of moesin by E2 and TAM in Ishikawa cells was not altered by inhibition of the 
ERK1/2 cascade with PD98059 (Fig. 11A-B). On the other hand, blockade of ER with ICI 182,780 
or of G proteins with pertussis toxin (PTX) completely abolished moesin activation in Ishikawa 
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cells (Fig. 11A-B) and ESC (Fig. 11D-E). In addition, interference with the kinase responsible for 
Thr
558
-phosphorylation of moesin, Rho-associated kinase (ROCK-2), using the inhibitor Y-27632 
(ROCKi) also resulted in blockade of moesin phosphorylation in the presence of E2 or TAM (Fig. 
11A-B, D-E). RAL was not effective in modulating moesin phosphorylation in Ishikawa or ESC 
(Fig. 11C, F), and the addition to RAL of ICI 182,780, PD 98059 or Y-27632 reduced moesin 
phosphorylation to a level below baseline. 
The presence of ERα and ERβ in Ishikawa cells is not constant in culture, therefore, we checked the 
expression of these receptors with western analysis, that revealed both ERα and ERβ in Ishikawa 
cells and ESC, as well as in ER+ T47D breast cancer cells that were used as control (Fig. 11G-H). 
 
3.24-Estradiol and tamoxifen, but not raloxifene, induce the interaction of ERα with Gα13 and 
the later signaling to ROCK-2 and to the actin cytoskeleton in Ishikawa cells 
We previously identified that ERα targets the actin-binding protein moesin via the interaction with 
the G protein, Gα13, which starts a cascade leading to recruitment of the Rho-associated kinase, 
ROCK-2 [64-65]. In order to test if the differential behaviour of E2 and TAM vs. RAL might be 
due to a distinct activation of this process, we did co-immunoprecipitation studies in Ishikawa cells 
to test the interaction of ERα and Gα13 in the presence of the compounds under study. These 
experiments showed that the interaction between ERα and Gα13 is enhanced in the presence of E2 
and TAM, while it is not affected by RAL (Fig. 12A). 
In addition, in the presence of E2, ROCK-2 is functionally activated, as shown by enhanced Thr-
phosphorylation of the bait protein myelin basic protein (MBP) by ROCK-2 immunoprecipitates 
(IP) obtained from Ishikawa cells (Fig. 12B). ROCK-2 activation by E2 was prevented by blocking 
G proteins with PTX (Fig. 12B). In comparison, TAM resulted in a weak but visible recruitment of 
ROCK-2, while no ROCK-2 activation was seen in the presence of RAL (Fig. 12B). 
 
Marina Inés Flamini 
20 
 
In agreement with the previous results, the remodeling of the actin cytoskeleton induced by E2 or 
TAM in ESC was dependent on ER, G proteins and ROCK-2, as shown by actin staining in the 
presence or absence of the specific inhibitors (Fig. 12C-E). 
 
3.25-Tamoxifen, but not raloxifene, inhibits moesin activation by E2 in Ishikawa cells 
The SERMs TAM and RAL compete with estrogens for binding to estrogen receptors and may 
block estrogen action in some instances. Co-treatment of Ishikawa cells with E2 (1 nM) in 
association with increasing concentrations of TAM or RAL revealed that the E2-induced moesin 
activation is counteracted by TAM, even at low concentrations (Fig. 13A), while it is not affected 
by RAL (Fig. 13B). 
 
3.26-Effects of estradiol, tamoxifen and raloxifene on endometrial cancer cell motility and 
invasion 
To delineate whether the biochemical changes observed with E2 and TAM in normal endometrial 
cells and in Ishikawa cells are associated with effects on cell motility, we performed in vitro 
migration assays. After partially scraping Ishikawa cells (growth-inhibited with Cytosine β-D-
arabinofuranoside hydrochloride,) out of the cell culture dish, we monitored the movement of the 
remaining cells for the following 48 hours. Exposure to E2, and to a lesser extent to TAM, resulted 
in an enhanced migration toward the scraped area (Fig. 14A-B). On the opposite, RAL had no 
visible effect on Ishikawa cell motility (Fig. 14A-B). The co-administration of TAM or RAL with 
E2 (all at 1 nM) both resulted in a blockade of Ishikawa cell motility induced by E2 (Fig. 14C-D). 
In addition to assaying horizontal motility, we performed three-dimensional invasion assays to test 
the effect of estrogen or SERMs on Ishikawa cell invasive properties. Administration of E2 to 
growth-inhibited Ishikawa cells resulted in enhanced invasion of the matrix (Fig. 15A-C). The 
effect of E2 was blocked by the ER-antagonist ICI 182,720 and by the G protein inhibitor PTX 
(Fig. 15A-C). In addition, co-treatment with E2 plus TAM or E2 plus RAL significantly reduced 
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the effect of estradiol (Fig. 15A-C). The administration of either TAM or RAL alone did not 
increase the invasive behavior of Ishikawa cells (Fig. 15A-C). 
 
3.3-Signaling cascades of ERα to moesin in T47-D, Ishikawa and ESC 
The key finding of this work is that ERα uses the actin controller moesin in endometrial and breast 
to induce a rapid cytoskeletal remodeling that supports the migration and invasion of the cells. In 
the presence of its ligand, ERα recruits a Gα13/RhoA/ROCK-2/Moesin (Fig. 16). This turns into 
moesin phosphorylation and translocation to the sites where the actin cytoskeleton and the cell 
membrane are actively remodeled. 
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4-DISCUSSION 
Estrogen exhibits a broad spectrum of physiological functions ranging from regulation of the 
menstrual cycle and reproduction to the modulation of bone density, brain function, and cholesterol 
mobilization. However, estrogen is also associated with pathological complications particularly 
with the onset of gynaecological malignancies including breast cancer and endometrial cancer. 
 
In the early 1970s it was reported that there was a 20–35% increase in incidence of endometrial 
cancer in Western Caucasian women who had undergone estrogen-only therapy [73]. Subsequently, 
various clinical and epidemiological investigations, with support from studies in cell culture and 
animal models, have demonstrated the involvement of estrogen in the development and/or 
progression of the disease. Estrogen is now considered the classic etiological factor for endometrial 
carcinogenesis, most endometrial cancers are type I estrogen-associated endometrioid 
adenocarcinomas. In 2002, the US National Toxicology Program listed steroidal estrogens as 
carcinogens for the first time. The report cites data from human epidemiological studies that show 
an association between estrogen-replacement therapy and an increase in the risk of endometrial 
cancer, as well as a less consistent increase in the risk of breast cancer. SERMs were initially 
envisioned as drugs that would replace estrogen therapy in alleviating the symptoms that are 
associated with menopause without the carcinogenic effects of estrogen in the mammary gland and 
uterus.  
 
SERMs block the action of estrogen in the breast and other tissues by occupying ERs and inducing 
conformational changes that prevent the interaction of the receptors with coactivators [74]. The 
current understanding of the mechanism of action of these drugs is that given the differences in the 
expression of the coactivators or co-repressors of ERs in different cells and tissues, each SERM will 
turn into a specific spectrum of bodily effects. Tamoxifen was first introduced into the clinics in the 
1970s and is used to treat women with hormone-sensitive breast cancer. In addition to its anti-
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estrogenic function in the breast, TAM is characterized by an unwanted stimulatory action on the 
endometrium, which turns into a higher rate of endometrial hyperplasia and cancer [75].  
 
RAL has been initially approved for the prevention and treatment of osteoporosis in 
postmenopausal women. However, it also prevents breast cancer in osteoporotic women or in 
women at high risk for breast cancer without increasing the incidence of endometrial cancer [76].  
 
Local invasiveness and distant metastasis are the foremost causes of breast cancer-related morbidity 
and death. TAM has been previously found to alter breast cancer cell adhesion, migration and 
invasion [70]. In the first part of this thesis, we find that RAL, like TAM, slightly increases T47-D 
breast cancer cell migration and invasion when administered alone. However, in the presence of 
estradiol, which potently increases breast cancer cell movement, both SERMs act as anti-estrogens, 
resulting into a marked blockade of both horizontal cell migration and invasion of three-
dimensional matrices. These complex actions on breast cancer cell motility are plaid through the 
regulation of the actin cytoskeleton of breast cancer cells via a set of molecular steps that converge 
on the ERM protein, moesin.  
 
The ERM actin-binding proteins, including moesin, function as linkers between the actin 
cytoskeleton and plasma membrane proteins. By interacting with actin, activated ERMs induce 
actin depolymerisation and re-assembly toward the cell membrane edge, supporting the formation 
of cortical actin complexes [77]. These complexes help the formation of molecular bridges between 
the actin cytoskeleton, integrins and focal adhesion complexes within ruffles and pseudopodia and 
are critical for cell movement [78].These structures assist the attachment of cells to the extracellular 
matrix and generate the locomotive forces for cell movement.  
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In quiescent conditions moesin exists in an auto-inhibited conformation and phosphorylation of 
Thr
558
 within the C-terminal actin binding domain by the Rho-associated kinase (ROCK), results in 
a conformational change and in the association with the scaffold protein, ezrin/radixin/moesin-
binding protein 50 (EBP50) on moesin’s NH2-terminal end and with F-actin on moesin’s COOH-
terminal end to mediate the linkage of microfilaments to membranes in cell surface microvilli [71]. 
Recent evidence indicates that proteins of the ERM family have important regulatory roles in cancer 
biology. For instance, ezrin is over-expressed in highly aggressive sarcomas [79-80] as well as in 
breast cancer, being associated with higher metastasis rate [81]. Likewise, moesin expression and 
sub-cellular localization have been found to be deranged in metastatic breast cancers [64]. 
 
Estradiol induces moesin phosphorylation in human endothelial [65] and breast cancer cells [64] 
through a set of rapid signalling actions. RAL acts in a similar fashion by rapidly activating moesin 
and thus promoting actin cytoskeletal remodelling and the formation of cortical actin complexes 
and specialized membrane protrusions. These actions explain the weak promotion of breast cancer 
cell movement induced by RAL. 
 
However, when estradiol and RAL are provided simultaneously, RAL inhibits the estradiol-
dependent recruitment of moesin in a concentration-related fashion. Notably, the higher RAL 
concentrations used in this study are in the range of the serum concentrations of this SERM found 
with the doses used in the clinical setting (60 mg/day) [82].  
The existence of differential clinical effects of RAL related to the concentration is well-established. 
For instance, low concentrations of RAL inhibit the growth of leiomioma cells, whereas higher 
concentrations of RAL have promoting effects [83]. In parallel, high RAL concentrations promote 
endometrial cancer cell growth, whereas lower concentrations are ineffective [84]. To explain such 
variable responses it has been proposed that RAL may differently alter the expression of ERs, the 
ratio of ERα/ERβ as well as the expression of cofactors at different concentrations [83]. 
Marina Inés Flamini 
25 
 
 
The blockade of the moesin-linked cytoskeletal remodelling induced by estrogen may be relevant 
for the efficacy of RAL in the setting of adjuvant hormonal therapy of ER+ breast cancer. This is 
supported by the evidence that ERM proteins are relevant regulators of the process of tumour 
metastasis [85]. For instance, high ezrin expression is associated with early development of 
metastasis of breast cancer, osteosarcoma tumours or adenocarcinomas [79, 81], and we have 
recently found overexpression of moesin in aggressive breast cancers [64]. 
 
Raloxifene is effective in blocking the promotion of breast cancer motility and invasion induced by 
E2 at concentrations expected to be achieved during standard therapies with this drug. This might 
imply that in addition to reducing the number of breast tumors diagnosed in postmenopausal 
women, RAL could also limit the tendency of the cancers to spread locally or at a distance, 
particularly in women with significant concentrations of estrogens in the breast, however this has 
not been investigated by clinical trials up to now. 
 
This report establishes that the actin-binding protein moesin is a target of SERMs, mediating their 
effects on breast cancer cell migration and invasion. In addition, this mechanism of action 
potentially offers insight into a number of other processes regulated by SERMs that involve cell 
movement, such as wound healing, that is reportedly accelerated by RAL [86]. 
In this report, the regulation of moesin by RAL or estrogen occurs within minutes and is quickly 
reverted thereafter, suggesting that it is enacted through an extra-nuclear signalling cascade of ERs 
[29]. Indeed, the activation of moesin by RAL appears to be mediated by G proteins and by the 
RhoA-associated kinase (ROCK-2). G proteins and ROCK-2 are established regulators of ERM 
proteins and of cytoskeletal architecture. In particular, ROCK-2 directly targets moesin and triggers 
its threonine phosphorylation [29]. Inhibitors of G proteins and of ROCK-2 consistently prevent the 
actions of RAL on moesin activation, horizontal migration and invasion of three-dimensional 
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matrices, suggesting that these mediators are necessary for the effects of RAL on breast cancer cell 
motility investigated in this study. In agreement, in response to different stimuli (including 
estrogens) ROCK-2 is recruited by a cascade involving the G protein Gα13 and the small GTPase 
RhoA, which then turns into the activation of ERM proteins and into cytoskeletal remodelling [71]. 
 
Taken together, our data suggest that the SERM raloxifene is able to alter ER+ breast cancer cell 
motility and invasive behaviour by regulating the actin cytoskeleton through the ERM protein 
moesin. Through this mechanism of action RAL appears to function as an antagonist against breast 
cancer cell migration and invasion induced by physiological concentrations of estradiol. This study, 
as every in vitro study, does not allow to predict if the effects of raloxifene on the motility of breast 
cancer cells will also be found in vivo. However, it provides a lead to follow for future 
investigations, giving potential molecular intermediates to target to modulate breast cancer using 
this SERM. In conclusion, in the first part of this thesis we highlight novel extra-nuclear 
mechanisms of action of the SERM raloxifene that might be important for the effects of this drug on 
the progression of ER+ breast cancers. 
 
In the second part of this thesis we studied the SERMs (RAL and TAM) in normal human 
endometrial stromal cells, ESC, as well as endometrial cancer cells Ishikawa. 
Deregulated endometrial cell remodeling, proliferation, adhesion, and interaction with the 
extracellular matrix are important to a variety of endometrial disorders, including dysfunctional 
uterine bleeding, infertility and endometriosis [87-89]. In addition, they play a relevant role in 
endometrial hyperplasia and cancer [90-93]. 
 
Related to the present study, ezrin is over-expressed in invasive endometrial cancers [94] and is 
required for in vitro invasion and metastatic potential of endometrial cancer cells [95]. 
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Endometriosis is also characterized by an increased expression of ezrin [96], possibly suggesting 
that this protein may have a role in the attachment of ectopic endometrial cells to the peritoneum. 
 
In the second part of the thesis we report that 17β-estradiol and tamoxifen rapidly activate a 
ER/Gα13/RhoA/ROCK/moesin signaling pathway in human endometrial Ishikawa cells and in 
primary cultured stromal cells. This cascade of events is related to the activation of actin 
remodeling and to the development of cell membrane morphological changes, as well as with the 
enhancement of cell horizontal movement and invasion of a three-dimensional matrix in normal and 
immortalized endometrial cells. These findings are consistent with recent reports in other 
endometrial cell lines that show estrogen activation of endometrial cancer movement through the 
recruitment of extra-nuclear signaling of ERs to mitogen-activated protein kinases and 
phosphatidylinositol-3-OH kinase [97-98]. In addition, the present results are in line with our recent 
reports, that identified the recruitment of the Gα13/RhoA/ROCK/moesin signaling cascade by 
estrogen and progesterone receptors in endothelial and breast cancer cells linked to cytoskeletal 
remodeling and cell movement and invasion [64-65, 99-100].  
A significant finding of this study is that RAL does not induce moesin phosphorylation, cytoskeletal 
changes or endometrial cell movement as opposed to E2 or TAM. The lack of agonistic activity of 
raloxifene on endometrial cells is well established both in vitro [101] and in animals [102], although 
the molecular basis of the different action vs. tamoxifen or estradiol at this level is not fully 
established. In contrast with these results, in the first part of this work we shows that RAL is able to 
trigger actin remodeling and moesin phosphorylation in ER+ breast cancer cells, leading to 
enhanced cell migration and invasion [103]. This discrepancy may indicate that the rapid extra-
nuclear signaling of ER triggered by SERMs may be to some extent cell-specific, similar to what is 
well established for gene regulation. 
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The potential relevance of the anti-estrogenic action of RAL in the endometrium have been recently 
highlighted by a large-scale clinical trial indicating that women receiving raloxifene are 
significantly protected from endometrial cancer as compared to normal controls and even more in 
comparison to women receiving TAM, where an increased risk is found [48]. This is consistent with 
studies that show that RAL blocks the stimulatory effect of estradiol on the endometrium [102], as 
well as the progression of transplanted endometrial carcinoma cells in mice [104]. Although the 
molecular basis for the different action of RAL vs. E2 or TAM in endometrial cells has not been 
completely elucidated, there is evidence that these ER ligands induce a different three-dimensional 
conformation of the ligand-binding domain of the receptor, which is related to a distinct pattern of 
interaction with co-activators or co-repressors in cells and thus with differential gene regulation 
[105]. Our work expands on this area, highlighting how different SERMs also turn into separate 
cellular actions because of differences in the recruitment of rapid, extra-nuclear pathways linked to 
the control of the actin cytoskeleton. 
On the other hand, in the presence of E2, which potently increases endometrial cell movement, both 
SERMs, TAM and RAL, act as anti-estrogens, resulting into a marked blockade of both horizontal 
cell migration and invasion of three-dimensional matrices, highlighting that both SERMs are able to 
interfere with ER activation by E2 and with its later extra-nuclear signaling. 
 
Our data also demonstrates that interference with the recruitment of the Gα13/RhoA/ROCK/moesin 
cascade in endometrial cells disrupts the E2- or TAM-induced enhanced attachment and migration. 
This might offer a potential new way to control the endometrial actions of E2 or TAM, with 
potential usefulness in a range of benign or malignant disorders where endometrial attachment to 
the extracellular matrix is deranged, such as dysfunctional uterine bleeding, endometriosis or 
endometrial cancer. 
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Although we identify a series of signaling steps that are differentially regulated by E2, RAL or 
TAM in endometrial cells, there are a number of unanswered questions. For instance, how does 
TAM promote phosphorylation of moesin and membrane modifications and yet it inhibits migration 
and to some extent, invasion when added to estradiol? And why is it that RAL does not inhibit the 
phosphorylation of moesin induced by E2 and still it interferes with its effects on migration and 
invasion?  One likely explanation is that the functional regulation of cell migration and invasion is 
regulated through multiple, redundant signaling intermediates, and moesin is only one of the players 
in the game. Further elucidation of the role of this protein for endometrial cell movement or 
differentiation is required to have a better understanding of the fundamental biological differences 
in the actions of estrogen or SERMs on these cells. 
 
In conclusion, this thesis describes the differential regulation of cell membrane morphology, actin 
cytoskeleton remodeling and migration and invasion of endometrial cells by estradiol, tamoxifen 
and raloxifene. Through a different regulation of ER extra-nuclear signaling, estradiol and 
tamoxifen enhance endometrial cell cytoskeletal remodeling and movement, while raloxifene does 
not. These findings help to understand the molecular basis of the actions of estrogen and SERMs in 
endometrial cells, and could provide new rationale for the clinical findings on the endometrial 
actions of SERMs. 
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5-FIGURES 
 
          A 
 
               B 
 
 
Fig. 1. Raloxifene induces a rapid rearrangement of the actin cytoskeleton and of cell membrane morphology in 
T47-D breast cancer cells. (A) T47-D breast cancer cells were treated with RAL (10-8 M) for 2, 5, 10, 15, 20, 30 or 60 
minutes or (B) for 15 minutes with different RAL concentrations (10-10-10-7 M). Phalloidin staining (in red) shows the 
modifications of the actin fibres and the formation of specialized cell membrane structures. Yellow arrows indicate 
membrane ruffles and pseudopodia. Nuclei are counterstained in blue. 
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Fig. 2. Raloxifene induces a rapid activation of the actin-binding protein, moesin. (A) T47-D breast cancer cells 
were treated with RAL (10-8 M) for 2, 5, 10, 15, 20, 30 or 60 minutes or (B) for 15 minutes with different RAL 
concentrations (10-10-10-7 M).  Thr558-moesin phosphorylation is shown in the lower boxes. Wild-type, un-
phosphorylated moesin expression is shown in the upper boxes as loading control. 
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Fig. 3. Raloxifene effects on T47-D breast cancer cell horizontal migrations. Cytosine β-D-arabinofuranoside 
hydrochloride (10µM), a selective inhibitor of DNA but not RNA synthesis was used 1 hour before treatment to arrest 
cell proliferation. T47-D breast cancer cells were scraped out of the cell culture dish with a razor blade at the beginning 
of the experiment and then treated with RAL in different concentrations (10-10-10-7 M) for 48 hours. Horizontal cell 
migration was measured as the number of cells crossing the starting line or as the mean migration distance from the 
starting line. (A) shows sample images of horizontal migration in the different conditions, the black lines indicate the 
mean migration distances. (B) show the quantitative analysis in terms of mean cell numbers or mean migration length. 
Data are expressed as the mean ± SD of three separate experiments. * = P ≤ 0.05 vs. control. 
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Fig. 4. Raloxifene inhibits actin and cell membrane remodeling and moesin activation induced by estradiol. (A) 
T47-D breast cancer cells were treated for 15 minutes with E2 (10-8 M) or E2 + RAL in different concentrations (10-10-
10-7 M). Phalloidin staining (in red) shows the modifications of the actin fibres and the formation of specialized cell 
membrane structures. Yellow arrows indicate membrane ruffles and pseudopodia. Nuclei are counterstained in blue. (B-
D) T47-D breast cancer cells were treated for 15 minutes with E2 (B - 10-8 M; C - 10-9 M; D - 10-10 M) or E2 + RAL in 
different concentrations (10-10-10-7 M).  Thr558-moesin phosphorylation is shown in the lower boxes. Wild-type, un-
phosphorylated moesin expression is shown in the upper boxes as loading control. 
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Fig. 5. Raloxifene inhibits T47-D breast cancer cell horizontal migrations induced by estradiol. Cytosine β-D-
arabinofuranoside hydrochloride (10µM), a selective inhibitor of DNA but not RNA synthesis was used 1 hour before 
treatment to arrest cell proliferation. T47-D breast cancer cells were scraped out of the cell culture dish with a razor 
blade at the beginning of the experiment and then treated with E2 (10-8 M) or E2 + RAL in different concentrations (10-
10-10-7 M) for 48 hours. Horizontal cell migration was measured as the number of cells crossing the starting line or as 
the mean migration distance from the starting line. (A) shows sample images of horizontal migration in the different 
conditions, the black lines indicate the mean migration distances. (B) show the quantitative analysis in terms of mean 
cell numbers or mean migration length. Data are expressed as the mean ± SD of three separate experiments. * = P ≤ 
0.05 vs. E2. 
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Fig. 6. Raloxifene signals to moesin and to the actin cytoskeleton via a rapid ER/G protein/ROCK-dependent 
extra-nuclear cascade. T47-D breast cancer cells were treated for 15 minutes with E2 (10-8 M) or RAL (10-8 M) in the 
presence or absence of the pure ER antagonist ICI 182,780 (ICI – 100 nM), of the MAP kinase inhibitor PD98059 (PD - 
5 M), or of the G protein inhibitor, pertussis toxin (PTX – 100 ng/mL) or of the ROCK-2 inhibitor, Y-27632 (ROCKi - 
10 M). (A) Phalloidin staining (in red) shows the modifications of the actin fibres and the formation of specialized cell 
membrane structures. Yellow arrows indicate membrane ruffles and pseudopodia. Nuclei are counterstained in blue. (B) 
Thr558-moesin phosphorylation is shown in the lower boxes. Wild-type, un-phosphorylated moesin expression is shown 
in the upper boxes as loading control. 
 
 
 
 
 
 
 
 
Marina Inés Flamini 
36 
 
 
A 
 
 
B 
 
 
 
Fig. 7. Raloxifene alters T47-D breast cancer cell horizontal migration through an ER/G protein/ROCK-
dependent cascade. Cytosine β-D-arabinofuranoside hydrochloride (10µM), a selective inhibitor of DNA but not RNA 
synthesis was used 1 hour before treatment to arrest cell proliferation. T47-D breast cancer cells were scraped out of the 
cell culture dish with a razor blade at the beginning of the experiment and then treated for 48 hours with E2 (10-8 M) or 
RAL (10-8 M) in the presence or absence of the pure ER antagonist ICI 182,780 (ICI – 100 nM), of the MAP kinase 
inhibitor PD98059 (PD - 5 M), or of the G protein inhibitor, pertussis toxin (PTX – 100 ng/mL) or of the ROCK-2 
inhibitor, Y-27632 (ROCKi - 10 M). Horizontal cell migration was measured as the number of cells crossing the 
starting line or as the mean migration distance from the starting line. (A) shows sample images of horizontal migration 
in the different conditions, the black lines indicate the mean migration distances. (B) show the quantitative analysis in 
terms of mean cell numbers or mean migration length. Data are expressed as the mean ± SD of three separate 
experiments. * = P ≤ 0.05 vs. Ral. 
 
 
 
 
 
 
 
 
Marina Inés Flamini 
37 
 
 
   
  A                                                                                                              B 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Effects of raloxifene on T47-D breast cancer cell invasion. T47-D breast cancer cells were seeded on top of an 
invasion chamber and then treated with cytosine β-D-arabinofuranoside hydrochloride (10µM) to arrest cell 
proliferation. The cells were then treated for 24 hours with E2 (10-8 M), RAL (10-8 M) or Tam (10-8 M), in the presence 
or absence of the pure ER antagonist ICI 182,780 (ICI – 100 nM), of the G protein inhibitor, pertussis toxin (PTX – 100 
ng/mL) or of the ROCK-2 inhibitor, Y-27632 (ROCKi - 10 M). Other cells received a combination of E2 (10-8 M) + 
RAL in different concentrations (10-10-10-7 M). The invading cells were photographed at 100  magnification and 
counted in the central field of triplicate membranes. (A) Representative images in chambers with matrigel are shown. 
The numbers under the picture indicate the mean number of invading cells ± SD from three separate experiments. (B) 
Shows the calculated invasion indexes. 
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Fig. 9. Estradiol and tamoxifen, but not raloxifene, induce a rapid rearrangement of the actin cytoskeleton and 
cell membrane in normal and tumoral endometrial cells. (A-C) Ishikawa cells (human endometrial adenocarcinoma) 
were treated with estradiol (E2), tamoxifen (TAM) or raloxifene (RAL) at different concentrations (10
-10
-10
-7
 M) for 15 
minutes. Phalloidin staining (in red) shows the modifications of the actin fibres and the formation of specialized cell 
membrane structures. Yellow arrows indicate membrane ruffles and pseudopodia. Nuclei are counterstained in blue. 
The remodeling of actin fibres and the morphological changes of the membrane were quantified by assessing the 
intensity of the actin fluorescence after conversion of the coloured pixels to greyscale using the Leica QWin image 
analysis and processing software. This analysis was performed selecting random boxes including the extra- and intra-
cellular space across the membrane, and the linear intensity of the signal was spatially recorded. We sampled five areas 
per each cell, and we repeated this on 30 different cells per experimental condition. The upper graphs in Fig. 1A-C 
show the analysis of sample boxes (displayed in white in the lower images) used for the measurement. These measures 
allowed to identify the thickness of the membrane, that is indicated at the side of each treatment set. (D) Normal human 
endometrial stromal cells (ESC) were treated with E2 10-9 M, TAM 10-9 M or RAL 10-9 M for 15 minutes. Details of 
the staining are the same as in A-C. 
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Fig. 10. Estradiol and tamoxifen, but not raloxifene, induce a rapid phosphorylation of the actin-binding protein, 
moesin in normal and tumoral endometrial cells. (A-C) Ishikawa cells were treated with E2, TAM and RAL at 
different concentrations (10-10-10-7 M) for 15 minutes. Thr558-moesin phosphorylation is shown in the lower boxes. 
Wild-type, un-phosphorylated moesin expression is shown in the upper boxes as loading control. (D) ESC were treated 
with E2 10-9 M, TAM 10-9 M and RAL 10-9 M for 15 minutes. Thr558-moesin phosphorylation is shown in the lower 
boxes. Wild-type, un-phosphorylated moesin expression is shown in the upper boxes as loading control. 
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Fig. 11. Estradiol and TAM signal to moesin and to the actin cytoskeleton via a rapid extra-nuclear ER/G 
protein/ROCK cascade. Ishikawa and normal human ESC were treated for 15 minutes with E2 10-9 M, TAM 10-9 M or 
RAL 10-9 M in the presence or absence of the pure ER antagonist ICI 182,780 (ICI – 100 nM), of the MAP kinase 
inhibitor PD98059 (PD - 5 M), or of the G protein inhibitor, pertussis toxin (PTX – 100 ng/mL) or of the ROCK-2 
inhibitor, Y-27632 (ROCKi - 10 M). Thr558-moesin phosphorylation is shown in the lower boxes. Wild-type, un-
phosphorylated moesin expression is shown in the upper boxes as loading control. (A-C) Ishikawa cells (D-F) ESC. (G) 
Western blot analysis of ERα was perform, in Ishikawa, ESC and T47-D cells. Actin expression is shown in the lower 
boxes as loading control. (H) Western blot analysis of ERβ was perform, in Ishikawa, ESC and T47-D cells. Actin 
expression is shown in the lower boxes as loading control. 
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Fig. 12. ERα signals to moesin and to the actin cytoskeleton via Gα13 and ROCK2 (A) Ishikawa cells were exposed 
for 15 min to E2 (10-9 M), TAM (10-9 M) or RAL (10-9 M). Cell protein extracts were immunoprecipitated with an Ab. 
vs. Gα13 and the IPs were assayed for co-immunoprecipitation of ERα. The membranes were re-blotted for Gα13 to 
show equal input. B) Ishikawa cells were treated for 15 min with E2 (10-9 M), TAM (10-9 M) or RAL (10-9 M) in the 
presence or absence of the G protein inhibitor, PTX (100 ng/ml). Protein extracts were immunoprecipitated with an Ab. 
vs. ROCK-2 and the IPs were used to perform kinase assays using de-phosphorylated myelin basic protein (MBP) as a 
bait. The lower box shows phosphorylation of MBP, the upper box the re-blotted for ROCK-2 to show equal input. (C-
E) Phalloidin staining (in red) shows the modifications of the actin fibres and the formation of specialized cell 
membrane structures in ESC. Yellow arrows indicate membrane ruffles and pseudopodia. Nuclei are counterstained in 
blue.  
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Fig.13. Tamoxifen inhibits the activation of moesin induced by estradiol. (A) Ishikawa cells were treated for 15 
minutes with E2 (10-9 M) or E2 (10-9 M) + TAM in different concentrations (10-10-10-7 M). Thr558-moesin 
phosphorylation is shown in the lower boxes. Wild-type, un-phosphorylated moesin expression is shown in the upper 
boxes as loading control.(B) Ishikawa cells were treated for 15 minutes with E2 (10-9 M) or  E2 (10-9 M) + RAL in 
different concentrations (10-10-10-7 M). Thr558-moesin phosphorylation is shown in the lower boxes. Wild-type, un-
phosphorylated moesin expression is shown in the upper boxes as loading control. 
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Fig. 14. Effects of estradiol, tamoxifen or raloxifene on Ishikawa cell horizontal migration. Cytosine β-D-
arabinofuranoside hydrochloride (10µM), a selective inhibitor of DNA but not RNA synthesis was used 1 hour before 
treatment to arrest cell proliferation. Endometrial cancer cells were scraped out of the cell culture dish with a razor 
blade at the beginning of the experiment and then treated with E2 , TAM or RAL (10-9 M) for 48 hours. Horizontal cell 
migration was measured as the mean ± SD of migration distance from the starting line. (A) Shows sample images of 
horizontal migration in the different conditions, the black lines indicate the mean migration distances. (B) Shows the 
quantitative analysis in terms of mean migration length ± SD. Dates are expressed as the mean ± SD of three separate 
experiments. * = P ≤ 0.05 vs. control. (C-D) Ishikawa cells were treated with E2 (10-9 M), E2 (10-9 M) + TAM (10-9 M) 
or E2 (10-9 M) + RAL (10-9 M)) for 48 hours. Horizontal cell migration was measured as the mean migration distance ± 
SD from the starting line. (C) Shows sample images of horizontal migration in the different conditions, the black lines 
indicate the mean migration distances. (D) Shows the quantitative analysis in terms of mean of migration length ± SD. 
Dates are expressed as the mean ± SD of three separate experiments. * = P ≤ 0.05 vs. E2. 
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Fig. 15. Effects of estradiol, tamoxifen or raloxifene on Ishikawa cell invasion. Endometrial cancer cells were 
seeded on top of a Matrigel invasion chamber and then treated with cytosine β-D-arabinofuranoside hydrochloride 
(10µM) to arrest cell proliferation. The cells were then treated for 24 hours with E2 (10-9 M), in the presence or absence 
of the pure ER antagonist ICI 182,780 (ICI – 100 nM), of the G protein inhibitor, pertussis toxin (PTX – 100 ng/mL) or 
RAL (10-9 M) or TAM (10-9 M). Other cells received a combination of E2 (10-9 M) + TAM (10-9 M) or E2 (10-9 M) + 
RAL (10-9 M). The invading cells were photographed at 100  magnification and counted in the central field of 
triplicate membranes. (A) Indicates the mean number of invading cells ± SD from three separate experiments. * = P ≤ 
0.05 vs. Con. ** = P ≤ 0.05 vs. E2. (B) Shows the calculated invasion indexes. * = P ≤ 0.05 vs. Con. ** = P ≤ 0.05 vs. 
E2. (C) Shows sample images of invasion in the different conditions.  
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Fig. 16. Signaling cascades of ERα to moesin and cell movement in breast cancer T47-D cells and endometrial 
cells. 
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7-MATERIALS AND METHODS 
7.1-Cell cultures and treatments 
The human breast carcinoma cell line T47-D was obtained from the American Type Culture 
Collection. T47-D cells were routinely grown in RPMI 1640 supplemented with L-glutamine (2 
mM), 10% fetal bovine serum.  
 
The immortalized Ishikawa human endometrial adenocarcinoma cell line was obtained from the 
European Collection of Cell Culture (ECACC, Salisbury, UK). Ishikawa cells were grown in 
phenol-red free MEM supplemented with L-glutamine (2mM), 10% fetal bovin serum, 1% non-
essential amino acids.  
 
Human endometrial stromal cells (ESC) were obtained from 10 women undergoing surgical 
procedures requiring endometrial biopsy (diagnostic or operative hysteroscopy, diagnostic or 
operative laparoscopic procedures). These patients were included only when free of oral 
contraceptives, progestins, GnRH analogues or antagonists, or other hormonal medications for at 
least 3 months. Women with previous autoimmune, neoplastic, hepatic, or thyroid disorders were 
excluded from the study. All women were younger than 40 years and older than 17; the median age 
was 30 ± 7 years. All samples were collected during the follicular phase, based on the last menstrual 
period and histological examination of the samples. Each patient signed a written informed consent, 
and approval for this study was granted by the local institutional human investigations committee. 
ESC were obtained with the method described by Viganò [106]. Endometrial cells were cultured to 
sub-confluence in phenol-red free DMEM with 10% FBS and antibiotics. 
 
T47-D, Ishikawa and ESC were expanded in medium containing normal FBS. 24 hours before 
treatments all cells were shifted to medium containing charcoal-stripped FBS with no detectable 
amounts of sex steroids. Before experiments investigating non-transcriptional effects, T47-D 
Marina Inés Flamini 
53 
 
Ishikawa or ESC were kept in culture medium containing no FBS for 8 hours. All cells were 
incubated in a humidified tissue culture incubator at 37°C, 5% CO2 atmosphere. 
 
Raloxifene was obtained from Eli Lilly Research Laboratories, 17β-estradiol, tamoxifen, PTX (G 
proteins inhibitor), Y-27632(ROCK-2 inhibitor), PD98059 (ERK1/2 MAPK cascade inhibitor) were 
from Sigma-Aldrich (Saint-Louis, MO), ICI 182,780 (ER antagonist) was obtained by Tocris 
Cookson (Avonmouth, UK). Raloxifene and PD98059 were dissolved in DMSO, 17β-estradiol, 
tamoxifene, and ICI 182,780 were dissolved in 100% ethanol. PTX and Y-27632, were dissolved in 
PBS. The final concentration of the solvents was 1µl of solvent per 1ml of medium 
  
7.2-Immunoblottings 
Cell lysates were separated by SDS-PAGE. Antibodies used were: mouse monoclonal anti-moesin 
(clone 38, Transduction Laboratories, Lexington, KY), goat polyclonal anti-Thr
558
-P-moesin (sc-
12895, Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal anti-ERα (clone 
TE111.5D11, NeoMarkers, Union City, CA), goat polyclonal anti-ERβ (N-19:sc-6820, Santa Cruz 
Biotechnology), goat polyclonal anti-ROCK-2 (C-20): sc1851; Santa Cruz Biotechnology), and 
rabbit polyclonal anti-Gα13 (clone A-20: sc-410; Santa Cruz Biotechnology), mouse monoclonal 
anti-Thr
98
-P-myelin Basic Protein PMBP (clone P12, upstate), goat polyclonal anti-Actin (C-11):sc-
1615 Santa Cruz Biotechnology). Primary and secondary Abs were incubated with the membranes 
with standard technique. Immunodetection was accomplished using enhanced chemiluminescence. 
 
7.3-Cell immunofluorescence 
Cells were grown on coverslips (2.5 x10
-4
 cell/ml) they were incubate for 24 hours and then 
exposed for 15 minutes to different treatments. Cells were fixed with 4% paraformaldehyde for 30 
min and permeabilized with 0.1% Triton for 5 min. Blocking was performed with PBS containing 
1% bovine serum albumin for 30 min. Cells were incubated with Texas Red-phalloidin (Sigma) for 
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30 min which stains filamentous(F)-actin. After washing the nuclei were counterstained with or 4'-
6-diamidino-2-phenylindole (DAPI) (Sigma) and mounted with Vectashield mounting medium 
(Vector Laboratories, Burlingame, CA). Immunofluorescence was visualized using an Olympus 
BX41 microscope and recorded with a high-resolution DP70 Olympus digital camera. Cell 
membrane thickness and the gray level of extracellular area, cell membrane as well as cytoplasm 
were quantitated using Leica QWin image analysis and image processing software (Leica 
Microsystems, Wetzlar, Germany). The remodeling of actin fibres and the morphological changes 
of the membrane were quantified by assessing the intensity of the actin fluorescence after 
conversion of the coloured pixels to greyscale using the Leica QWin image analysis and processing 
software. This analysis was performed selecting random boxes including the extra- and intra-
cellular space across the membrane, and the linear intensity of the signal was spatially recorded 
after visual identification by the examiner of the external and internal limits of the membrane . We 
sampled five areas per each cell, and we repeated this on 30 different cells per experimental 
condition. Each measurement of the extracellular, membrane or cytosol signal intensity in the 30 
different cells per condition were used to calculate means ± SD. 
 
7.4-Co-immunoprecipitation assays 
Ishikawa cells were harvested in 100 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 1 mM 
Na3VO4, 1 mM NaF, and 1 mM PMSF. Equal amounts of cell lysates were incubated with 1 g of 
precipitating Ab (Gα13) overnigth at 4°C under gentle agitation. 25 L of a 1:1 protein A-agarose 
slurry were added, and the samples were rolled at 4°C for another hour. The samples were then 
pelleted, washed, and resuspended in 50 L of 2X Laemmli buffer for immunoblotting. 
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7.5-Kinase assays 
Ishikawa cells were harvested in 20 mM Tris-HCl, 10 mM EDTA, 100 mM NaCl, 0.5% IGEPAL 
and 0.1 mg/mL PMSF. Equal amounts of cell lysates were immunoprecipitated with Rhotekin RBD 
agarose (14-383, upstate) vs. ROCK-2 (C-20, Santa Cruz). The IPs were washed three times with 
buffer containing 20 mM Tris-HCl, 10 mM EDTA, 150 mM NaCl, 0.1% IGEPAL and 0.1 mg/mL 
PMSF. For ROCK-2 activity assay, two additional washes were performed in kinase assay buffer 
(20 mM MOPS, 25 mM β-glycerophosphate, 5 mM EGTA, 1 mM DTT) and the samples were 
therefore resuspended in this buffer. 5 µg of de-phosphorylated Myelin Basic Protein (Upstate) 
together with 500 µM ATP and 75 mM MgCl2 were added to each sample and the reaction was 
started putting the samples at 30°C for 20 min. The reaction was stopped on ice and by 
resuspending the samples in Laemmli Buffer. The samples were separated with SDS-PAGE and 
Western analysis was performed using antibodies recognizing Thr98-P-myelin Basic Protein (05-
429, upstate). 
 
7.6-Cell migration assays 
Cell migration was assayed with razor scrape assays as previously described [65]. Briefly, a razor 
blade was pressed through the confluent cells monolayer into the plastic plate to mark the starting 
line. Cells were swept away on one side of that line then were washed, and 2.0 mL of medium 
containing steroid-deprived FBS were added. Cytosine β-D-arabinofuranoside hydrochloride 
(Sigma) (10µM), a selective inhibitor of DNA synthesis which doesn’t inhibit RNA synthesis was 
used 1 h before the test substance was added. Migration was monitored for 48 hours. Every 12 h 
fresh medium and treatment were replaced. Cells were digitally imaged and migration distance was 
measured by using phase-contrast microscopy.  
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7.7-Cell invasion assay 
Cell invasion were assayed following the standard method by using the BD BioCoat
TM 
 Growth 
Factor Reduced (GR) Matrigel
TM
 Invasion Chamber (BD Bioscience, USA). In brief, after 
rehydrating the GFR Matrigel inserts, test substance were added to the wells of the BD Falcon
TM
 
TC Companion Inserts (no GRF Matrigel coating). An equal number of BD BioCoat
TM
 Control 
Inserts (no GFR Matrigel coating) were likewise prepared as control. Then 0.5 mL of T47-D cell 
suspension (density, 2.5  104 cells) were added to the inside of the inserts. The chambers were put 
in incubator at 37 °C, 5% CO2 atmosphere for 24 h. After incubation, the non-invading cells were 
removed from the upper surface of the membrane by “scrubbing” using cotton tipped swabs. Then 
the cells on the lower surface of the membrane were stained with Diff-Quick stain. The invading 
cells were observed and photographed under the microscope at 100  magnification. Cells were 
counted in the central field of triplicate membranes. The invasion index was calculated as 
follows: % invasion test cell/ % invasion control cell. 
 
7.8-Statistical analysis 
All values are expressed as (mean ±SD). Statistical analysis of the data was performed using one-
way analysis of variance (ANOVA) followed by Tukey-Kramer Multiple-Comparisons Test. p < 
0.05 was considered as statistically significant. 
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